健之佳(605266) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥2,294,216,877.71, a decrease of 0.85% compared to ¥2,313,981,509.90 in Q1 2024[3] - Net profit attributable to shareholders decreased by 35.85% to ¥33,525,576.37 from ¥52,259,604.68 in the same period last year[3] - Basic earnings per share fell by 35.29% to ¥0.22 from ¥0.34 in Q1 2024[4] - The net profit for Q1 2025 was CNY 33,544,104.45, a decrease of CNY 18,340,831.00 or 35.35% compared to Q1 2024[11] - The total profit for Q1 2025 was CNY 39,858,247.10, down by CNY 20,636,065.49 or 34.11% from the previous year[10] - Operating profit decreased to CNY 39,700,306.59, reflecting a decline of CNY 20,290,732.76 or 33.82% year-over-year[10] - Total operating revenue for Q1 2025 was approximately ¥2.29 billion, a slight decrease of 0.8% compared to ¥2.31 billion in Q1 2024[44] - Net profit for Q1 2025 was approximately ¥33.54 million, down 35.3% from ¥51.88 million in Q1 2024[45] - Operating profit for Q1 2025 was approximately ¥39.70 million, a decrease of 33.9% compared to ¥59.99 million in Q1 2024[45] Cash Flow and Assets - The net cash flow from operating activities increased by 78.17% to ¥180,297,093.28 compared to ¥101,194,323.06 in Q1 2024[3] - The cash flow from operating activities increased by CNY 79,102,770.22, representing a growth of 78.17% compared to the same period last year[11] - Cash and cash equivalents at the end of Q1 2025 were approximately ¥251.67 million, down from ¥353.63 million at the end of Q1 2024[49] - The company reported a net cash outflow from investing activities of approximately ¥22.72 million in Q1 2025, compared to a net outflow of ¥19.55 million in Q1 2024[49] - The company raised approximately ¥449.16 million in borrowings during Q1 2025, an increase from ¥245.48 million in Q1 2024[49] - The company experienced a net cash outflow from financing activities of approximately ¥107.99 million in Q1 2025, an improvement from a net outflow of ¥140.60 million in Q1 2024[49] - The total assets at the end of Q1 2025 were ¥10,114,515,355.63, down 4.79% from ¥10,623,265,828.75 at the end of the previous year[4] Operational Efficiency - The company's gross margin for retail pharmaceuticals improved by 2.22% due to enhanced promotional efficiency[6] - The company reported a significant reduction in expenses, with a growth rate of 4.74% compared to 19.98% in the previous year[6] - Inventory decreased by 9.67% to ¥2,825,299,981.31, indicating improved inventory turnover efficiency[9] - Inventory turnover efficiency is being improved through category planning adjustments and the introduction of high-quality private label products[37] - The company is slowing down store expansion and focusing on improving store and employee efficiency, with a strategy of "self-built + acquisition" for orderly expansion in planned areas[34] Business Strategy and Market Position - The company is accelerating its business transformation to offset the decline in medical insurance income by enhancing non-pharmaceutical business operations[6] - The company’s strategic focus remains on optimizing existing store structures and enhancing operational efficiency rather than aggressive expansion[17] - The company aims to focus on health management services and differentiate its product offerings to meet customer needs[33] - The company is actively exploring new sales channel models, including cross-border e-commerce, which generated over CNY 4 million in sales[28] - The company’s revenue from the pharmaceutical retail segment is expected to continue growing, supported by a differentiated store expansion strategy[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 17,350[14] - The company’s major shareholders include Shenzhen Changsi Industrial Development Co., holding 23,439,968 shares, representing a significant portion of the total shares[16] - The company’s actual controller, Lan Bo, and his spouse hold a combined 66.67% of the shares, indicating strong insider control[16] - The company’s total shareholding structure indicates a high concentration of ownership among the top shareholders, with the top 10 shareholders holding a significant portion of the total shares[16] Revenue Breakdown - Prescription drug revenue reached CNY 789,989,496.00, representing a year-on-year increase of 2.66%[25] - The online channel generated revenue of CNY 66,070.62 million, a growth of 22.13% year-on-year, accounting for 28.80% of total revenue[29] - The sales of health food increased by 14.97% compared to the previous year[26] - The company conducted 57 live broadcasts during the reporting period, achieving sales of CNY 26.31 million, a year-on-year increase of 45.8%[28] - The company’s revenue from the pharmaceutical retail segment showed a slight increase, with a total of 5,490 stores at the end of Q1 2025, reflecting a cautious expansion strategy[18]